Patent 12252506
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-pro
No PTAB proceedings on file. This patent has not been challenged through Inter Partes Review, Post-Grant Review, or Covered Business Method review at the USPTO. The absence is itself a signal — well-asserted patents eventually attract IPRs.
Cases on file (0)
Specific litigation cases in our database that name US patent 12252506. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Litigation Status of U.S. Patent 12,252,506
As of April 30, 2026, a comprehensive search of federal court dockets and patent litigation databases reveals no known litigation involving U.S. Patent 12,252,506.
The search included the following resources:
- PACER (Public Access to Court Electronic Records): A nationwide search of U.S. District Court, Bankruptcy Court, and Court of Appeals dockets for cases citing patent 12,252,506 returned no results.
- U.S. Court of Appeals for the Federal Circuit (CAFC): A review of the CAFC docket, the primary appellate court for patent cases, showed no pending or decided cases involving this patent.
- Unified Patents Portal: A search of this extensive patent litigation database for district court and Patent Trial and Appeal Board (PTAB) cases also yielded no results for patent 12,252,506.
The absence of litigation is not unusual, given that the patent was issued on March 18, 2025. Typically, a period of time elapses before infringement is detected and a lawsuit is filed.
It is noteworthy that on December 22, 2025, Niagen Bioscience, Inc. announced its acquisition of the full patent portfolio from The Queen's University of Belfast, including U.S. Patent 12,252,506, to which it previously held an exclusive license. This consolidation of ownership could streamline future enforcement actions. In a statement, Niagen Bioscience's CEO noted that owning the portfolio "further protects Niagen Bioscience shareholders against infringers." This suggests a potential willingness to enforce the patent rights, including those of patent 12,252,506, should infringement occur.
Generated 4/30/2026, 2:26:37 PM